New Immunological Markers in Chromoblastomycosis—The Importance of PD-1 and PD-L1 Molecules in Human Infection

New Immunological Markers in Chromoblastomycosis—The Importance of PD-1 and PD-L1 Molecules in Human Infection

The pathogenesis of chromoblastomycosis (CBM) is associated with Th2 and/or T regulatory immune responses, while resistance is associated with a Th1 response. However, even in the presence of IFN-γ, fungi persist in the lesions, and the reason for this persistence is unknown. To clarify the factors...

Full description

Bibliographic Details
Main Authors:	Italo N. Cavallone, Walter Belda, Caroline Heleno C. de Carvalho, Marcia D. Laurenti, Luiz Felipe D. Passero
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Series:	Journal of Fungi
Subjects:	chromoblastomycosis melanized fungi immunological response cell exhaustion PD-1 PD-L1
Online Access:	https://www.mdpi.com/2309-608X/9/12/1172

Similar Items

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

Response of chromoblastomycosis to voriconazole
by: Alexandre Moretti de Lima, et al.
Published: (2016-10-01)

Chromoblastomycosis: New Perspective on Adjuvant Treatment with Acitretin
by: Walter Belda, et al.
Published: (2023-11-01)

The Role of PD-1 in Acute and Chronic Infection
by: Jil M. Jubel, et al.
Published: (2020-03-01)

The PD-1/PD-L1 Axis in the Biology of MASLD
by: Rosaria Maria Pipitone, et al.
Published: (2024-03-01)

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors
by: Catherine T. Le, et al.
Published: (2019-11-01)

Chromoblastomycosis evolving to sarcomatoid squamous cell carcinoma: A case report
by: Walter Belda Jr., et al.
Published: (2021-08-01)

PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
by: Ramón Cantero-Cid, et al.
Published: (2018-10-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

The PD1: PD-L1/2 pathway from discovery to clinical implementation
by: Kankana Bardhan, et al.
Published: (2016-12-01)

Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2023-01-01)

Dermoscopy of chromoblastomycosis
by: Sweta Subhadarshani, et al.
Published: (2017-10-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
by: Mengling Wu, et al.
Published: (2022-03-01)

Regulation of PD-L1 expression in the tumor microenvironment
by: Ming Yi, et al.
Published: (2021-01-01)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2021-09-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
by: Kimberly Krueger, et al.
Published: (2022-09-01)

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules
by: Marialuigia Fantacuzzi, et al.
Published: (2024-02-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients
by: Zeinab Rajabian, et al.
Published: (2019-03-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
by: Kimberly Krueger, et al.
Published: (2022-10-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief
by: Daling Deng, et al.
Published: (2024-04-01)

Investigation of the PD-1 and PD-L1 Immune Checkpoint Molecules Throughout Healthy Human Pregnancy and in Nonpregnant Women
by: Matyas Meggyes, et al.
Published: (2020-08-01)

PD-1/PD-L Axis in Neuroinflammation: New Insights
by: Susanna Manenti, et al.
Published: (2022-06-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export
by: Fang-Fang Chen, et al.
Published: (2020-01-01)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
by: Yiru Long, et al.
Published: (2022-05-01)

Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-γ by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection
by: Shinya Goto, et al.
Published: (2020-02-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)